摘要
目的:评价重组人血小板生成素(rhTPO)对血小板减少的临床疗效、应用现状及影响因素。方法:采用流行病学病例对照观察研究方法,以2009年5月14日-2010年3月23日189例使用rhTPO的住院患者为研究对象,使用重组人白细胞介素-11(rhIL-11)的170例住院患者作为同期对照,通过PASS系统追踪记录用药情况并动态监测血小板计数变化情况。结果:临床实际应用rhTPO差异较大,主要表现为未完全按照说明书推荐剂量使用、适应证范围扩大、用药疗程缩短、给药时机不一、患者病生理状况复杂;rhTPO和rhIL-11治疗血小板减少症的有效率分别为73.0%和57.6%(P<0.01)。结论:rhTPO用于多种原发病所致的血小板减少症的疗效优于rhIL-11,实际用药疗程和总剂量低于说明书推荐量即可达到预期效果,最佳给药时机为化疗后6～24h,化疗前预防给药对疗效提升无明显效应性,使用rhTPO后导致血小板过度升高的特征分布和安全性尚需扩大样本深入研究。
Objective：To evaluate the clinical effect,application and influence factors of recombinant human thrombopoietin（rhTPO） on thrombocytopenia.Methods：One hundred and eighty-nine inpatients treated with rhTPO were selected as the objectives from May 14,2009 to March 23,2010.And 170 hospitalized patients treated with recombinant human interleukin-11（rhIL-11） were selected as the comparison.PASS system recorded the medication and platelet growth situation by dynamic monitoring.Results：There existed big difference in clinical application of rhTPO.It was not used as the recommended dosage according to the specifications.This manifested in wider indications,shorter medication,the different administration time,and complex physical status of patients.The efficiency of rhTPO on thrombocytopenia was higher than that of rhIL-11（P 0.01）.Conclusion：The effect of rhTPO on thrombocytopenia caused by a variety of original disease were obviously superior to that of rhIL-11.Actual drug treatment and total dose below the recommended amount in the specifications can achieve the desired results.Optimal dosing opportunity was 6 to 24 hours after chemotherapy.Prevention administration before chemotherapy had no obvious effect on efficiency enhancement.In-depth research was still used to study platelet rising excessively caused by rhTPO and its safety.
出处
《中国药物应用与监测》
CAS
2011年第1期5-8,共4页
Chinese Journal of Drug Application and Monitoring
基金
军队十一五科技攻关课题(08G139)
